LifeStance Health Group, Inc. (NASDAQ:LFST) Receives $9.86 Consensus Price Target from Analysts

Shares of LifeStance Health Group, Inc. (NASDAQ:LFST) have been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are presently covering the stock, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $9.75.

LFST has been the topic of several recent analyst reports. JPMorgan Chase & Co. lifted their price target on LifeStance Health Group from $8.00 to $9.00 and gave the company a “neutral” rating in a research note on Thursday, May 14th. Zacks Research upgraded LifeStance Health Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, April 27th. Canaccord Genuity Group lifted their price target on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Barclays boosted their price objective on LifeStance Health Group from $8.00 to $9.00 and gave the stock an “overweight” rating in a research report on Friday, March 6th. Finally, Jefferies Financial Group upgraded LifeStance Health Group to a “strong-buy” rating in a research report on Thursday, March 12th.

Insider Buying and Selling

In related news, Director Darren M. Black sold 5,899,661 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total transaction of $47,315,281.22. Following the sale, the director owned 23,310,115 shares in the company, valued at $186,947,122.30. The trade was a 20.20% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Eric Shuey sold 243,362 shares of the business’s stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $8.02, for a total value of $1,951,763.24. Following the sale, the director owned 867,562 shares in the company, valued at $6,957,847.24. This represents a 21.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 6,868,057 shares of company stock worth $55,048,226 in the last 90 days. Insiders own 6.60% of the company’s stock.

Institutional Investors Weigh In On LifeStance Health Group

A number of institutional investors have recently made changes to their positions in LFST. Silversmith Partners I GP LLC bought a new stake in shares of LifeStance Health Group in the 4th quarter valued at about $100,842,000. AustralianSuper Pty Ltd bought a new stake in shares of LifeStance Health Group in the 3rd quarter valued at about $17,056,000. Vanguard Group Inc. grew its position in shares of LifeStance Health Group by 21.1% in the 4th quarter. Vanguard Group Inc. now owns 17,700,041 shares of the company’s stock valued at $124,608,000 after buying an additional 3,086,506 shares during the last quarter. Jennison Associates LLC grew its position in shares of LifeStance Health Group by 38.5% in the 1st quarter. Jennison Associates LLC now owns 10,228,801 shares of the company’s stock valued at $65,157,000 after buying an additional 2,843,388 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of LifeStance Health Group by 62.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 4,793,336 shares of the company’s stock valued at $26,363,000 after buying an additional 1,839,465 shares during the last quarter. Institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Trading Down 0.9%

Shares of LFST opened at $7.34 on Tuesday. LifeStance Health Group has a 52-week low of $3.74 and a 52-week high of $8.89. The business’s fifty day moving average is $7.20 and its 200-day moving average is $7.01. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.48 and a current ratio of 1.48. The firm has a market cap of $2.85 billion, a price-to-earnings ratio of 122.33 and a beta of 1.19.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.03. LifeStance Health Group had a return on equity of 1.56% and a net margin of 1.55%.The company had revenue of $403.48 million for the quarter, compared to analyst estimates of $387.46 million. The company’s revenue was up 21.2% on a year-over-year basis. Equities analysts anticipate that LifeStance Health Group will post 0.12 EPS for the current fiscal year.

LifeStance Health Group announced that its Board of Directors has authorized a share repurchase program on Wednesday, February 25th that permits the company to buyback $100.00 million in outstanding shares. This buyback authorization permits the company to reacquire up to 3.6% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s leadership believes its stock is undervalued.

LifeStance Health Group Company Profile

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.